Protalix BioTherapeutics (PLX) Q3 2024 earnings summary

Executive summary

• Completed all eight cohorts of the phase I PRX-115 trial for uncontrolled gout, showing dose-dependent uric acid reduction and favorable safety; phase II trial planned for H2 2025.

• Elfabrio commercialization continues with Chiesi, supported by global studies and increased investment.

• Strategic focus on rare renal diseases, leveraging the ProCellEx platform and exploring new modalities.

• Company is now debt-free after repaying all outstanding convertible notes using available cash in September 2024.

• Cash and cash equivalents stood at $27.4M at quarter-end, expected to cover capital needs for at least 12 months.

Financial highlights

• Q3 2024 product revenues reached $17.8M, up 75% year-over-year, driven by higher sales to Chiesi and Pfizer.

• Cost of goods sold increased 71% to $8.4M, reflecting higher sales volumes.

• R&D expenses decreased 19% to $3M due to completion of Fabry/Elfabrio clinical and regulatory programs.

• SG&A expenses fell 30% to $2.6M, mainly from lower salaries and professional fees.

• Net income was $3.2M ($0.04/share basic, $0.03/share diluted), compared to a net loss of $1.9M in Q3 2023.

Outlook and guidance

• Phase II PRX-115 trial targeted to start in H2 2025, with top-line results expected by late 2026 or early 2027.

• Continued collaboration with Chiesi on Elfabrio, including studies in Japan and other regions.

• Focused R&D on early-stage assets for rare renal diseases and plant-based drug delivery systems.

• Management expects continued significant R&D expenditures as new clinical programs advance.

• Revenues from license and R&D services are expected to remain minimal, except for potential regulatory milestone payments.